About XL Laboratories Private Limited
Data last updated:
XL Laboratories Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 March 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24239DL2000PTC104513. Its GSTIN is 08AAACX0157E1ZL (Rajasthan). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹3 Cr and a paid-up capital of ₹3 Cr. It is led by directors Ashok Kumar Bhargava and Rahul Bhargava.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Dsm 430 – 431 DLF Tower Shivaji Marg, New Delhi, Delhi, India – 110015.
As per the financials filed for FY 2025, the company reported a revenue of ₹95.4 Cr, a growth of 16% compared to the previous year. For the same year it recorded a net profit of ₹6.32 Cr (net margin 6.6%) and EBITDA of ₹13.5 Cr (EBITDA margin 14.1%). Revenue has grown at a compounded annual rate (CAGR) of 14% over three years and 16% over five years.
The company has about 370 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹15.15 Cr and satisfied charges of ₹12.6 Cr on record. Court records list 5 cases involving the company, including 3 filed by the company and 2 filed against it. The company has 7 deals on record (6 secondary share transfers, 1 funding round), with disclosed funding of ₹1 Cr; the latest was in March 2025. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Enicar Pharmaceuticals Private Limited with revenue of ₹97.81 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website xlrem.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressDsm 430 – 431 DLF Tower Shivaji Marg, New Delhi, Delhi, India – 110015
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of XL Laboratories Private Limited
The main business activity of XL Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of XL Laboratories Private Limited FY 2025 filings available
XL Laboratories Private Limited reported revenue of ₹95.4 Cr (up 16% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of XL Laboratories Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 16% over five years, including 16% growth in the latest year. EBITDA fell 42% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of XL Laboratories Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹95.4 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹13.5 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹6.32 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of XL Laboratories Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 6.6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of XL Laboratories are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of XL Laboratories Private Limited
XL Laboratories Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Enicar Pharmaceuticals Private Limited | ₹97.81 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Boisar, Maharashtra, India |
| Astonea Labs Limited | ₹97.71 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Chandigarh, India |
| Veer Chemie and Aromatics Pvt Ltd | ₹97.47 Cr (FY 2024) | •••• | •••• | 11.0% | •••• | Telangana, India |
| Pharma Chem Industries (Gujarat) Private Limited | ₹97.24 Cr (FY 2025) | •••• | •••• | 20.0% | •••• | Vapi, Gujarat, India |
| V S International Private Limited | ₹96.26 Cr (FY 2024) | •••• | •••• | 65.0% | •••• | Mumbai, Maharashtra, India |
| Yeluri Formulations Private Limited | ₹96.05 Cr (FY 2025) | •••• | •••• | -23.0% | •••• | Hyderabad, Telangana, India |
| Zyrex Healthcare Private Limited | ₹95.65 Cr (FY 2024) | •••• | •••• | 364972.0% | •••• | Pune, Maharashtra, India |
| XL Laboratories Private Limited this company | ₹95.4 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | New Delhi, Delhi, India |
| MCW Healthcare Private Limited | ₹95.35 Cr (FY 2024) | •••• | •••• | 16.0% | •••• | Madhya Pradesh, India |
| Surmount Laboratories Limited | ₹95.33 Cr (FY 2024) | •••• | •••• | -6.0% | •••• | Mumbai, Maharashtra, India |
| Ang Lifesciences India Limited Listed | ₹94.87 Cr (FY 2025) | •••• | •••• | -35.0% | •••• | Amritsar, Punjab, India |
Peers are the five companies nearest above and the five nearest below XL Laboratories by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of XL Laboratories Private Limited
XL Laboratories Private Limited is audited by AHMAD SHUKLA JAIN AND ASSOCIATES for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| AHMAD SHUKLA JAIN AND ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of XL Laboratories Private Limited
XL Laboratories has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashok Kumar Bhargava | Director | 11 Feb 2002 | 24 Years 8 Months | Current |
| Rahul Bhargava Also directs: Curemed Healthcare Private Limited | Director | 16 Mar 2002 | 24 Years 6 Months | Current |
Ownership and Shareholding of XL Laboratories Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of XL Laboratories Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Jan 2026 | Indian Overseas Bank | ₹1.37 Cr | Open |
| 17 Mar 2025 | Indian Overseas Bank | ₹1.45 Cr | Open |
| 16 Nov 2024 | Others | ₹5 Cr | Open |
| 23 Sep 2024 | Others | ₹35 Lakh | Open |
| 04 May 2024 | Others | ₹58 Lakh | Open |
Total charge records: 11 View all charges
Deals & Funding of XL Laboratories Private Limited
XL Laboratories Private Limited has 7 deals on record (6 secondary share transfers, 1 funding round), with disclosed funding of ₹1 Cr; the latest was in March 2025.
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Secondary share transfer | Undisclosed | Seller: an individual |
| Sep 2014 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 3 individuals |
| Mar 2013 | Secondary share transfer | Undisclosed | Seller: 3 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Seller: 3 individuals |
| Mar 2009 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 4 individuals |
Full deal history
All 7 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of XL Laboratories Private Limited
XL Laboratories Private Limited has 5 court cases on record: 3 filed by XL Laboratories, 2 filed against it. All cases are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 0 | 0 |
| District courts | 2 | 2 | 0 |
Cases on record (5 of 5)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South West, Delhi | Civil suit | Filed against the company by State | Disposed |
| District court, North West, Delhi | Civil suit | Filed against the company by State | Disposed |
| High Court of Rajasthan | Writ petition | Filed by the company against an individual | Disposed |
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against an individual | Disposed |
| High Court of Delhi | Court case (CS(OS)) | Filed by the company against Maiden Pharmaceuticals & Anr | Disposed |
Full case history
All 5 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at XL Laboratories Private Limited
XL Laboratories Private Limited has a workforce of 370 employees as of Oct 14, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on XL Laboratories Private Limited
XL Laboratories Private Limited has 3 board changes on record since 2002: 2 appointments and 1 cessation. The latest: Pradeep Bhargava ceased to be Director on 28 Jan 2009.
14 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for XL Laboratories Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by XL Laboratories Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of XL Laboratories Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of XL Laboratories Private Limited
XL Laboratories has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAACX0157E1ZL | Rajasthan | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of XL Laboratories Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XL Laboratories Private Limited
XL Laboratories is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 March 2000 (26+ years old) and is registered under CIN U24239DL2000PTC104513.
XL Laboratories reported revenue of ₹95.4 Cr for FY 2025 (up 16% YoY).
XL Laboratories has 2 current directors:
- Ashok Kumar Bhargava - Director
- Rahul Bhargava - Director
XL Laboratories reported a net profit of ₹6.32 Cr (net margin 6.6%) and EBITDA of ₹13.5 Cr (EBITDA margin 14.1%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of XL Laboratories is 14% over three years and 16% over five years. In the latest year (FY 2025) revenue rose 16%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of XL Laboratories is 08AAACX0157E1ZL, registered in Rajasthan. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of XL Laboratories is U24239DL2000PTC104513. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
XL Laboratories has 5 court cases on record: 3 filed by the company and 2 filed against it. Most are in the high courts.
XL Laboratories was incorporated on 16 March 2000, making it 26+ years old. It is registered with the Registrar of Companies, Delhi.
XL Laboratories has 7 deals on record (6 secondary share transfers, 1 funding round), with disclosed funding of ₹1 Cr; the latest was in March 2025.
The peers of XL Laboratories by revenue are Enicar Pharmaceuticals Private Limited, Astonea Labs Limited, Veer Chemie and Aromatics Pvt Ltd, Pharma Chem Industries (Gujarat) Private Limited, V S International Private Limited and 5 more, all in the Pharma industry (Formulations).